Inotek Pharma - Company & Market Research Reports

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts. It is focused on the development and commercialization of therapies for glaucoma and other serious diseases of the eye. The company's lead product candidate is Trabodenoson, formerly known as INO-8875, which is in Phase III clinical trials for lowering IOP. Trabodenoson has completed Phase 1, 2, and 3 clinical trials in subjects with OHT and POAG. Inotek was founded in 1999.

From
From
From
From
From
From
From
From
From
From
Glaucoma Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Glaucoma Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 586 Pages
From
From
From
From
From
Loading Indicator
adroll